The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
暂无分享,去创建一个
Maurice Hayot | Zouhair Tabka | Z. Tabka | C. Prefaut | M. Hayot | A. Zbidi | Christian Préfaut | H. Ben Saad | Helmi Ben Saad | Abdelkrim Zbidi
[1] A. Gulsvik,et al. Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. , 2006, Pulmonary pharmacology & therapeutics.
[2] J. Hankinson,et al. Interpretative strategies for lung function tests , 2005, European Respiratory Journal.
[3] C. Persson. Small airway relaxation--a forgotten medical need. , 2008, Pulmonary pharmacology & therapeutics.
[4] S. Spencer,et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.
[5] P. Calverley,et al. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease , 2001, Thorax.
[6] J E Cotes,et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[7] N. Anthonisen,et al. Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.
[8] S. Quadrelli,et al. Evaluation of bronchodilator response in patients with airway obstruction. , 1999, Respiratory medicine.
[9] A. Miller,et al. Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.
[10] A. Ramírez-Venegas,et al. Salmeterol reduces dyspnea and improves lung function in patients with COPD. , 1997, Chest.
[11] R. Zuwallack,et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.
[12] S. Kudoh,et al. Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. , 2007, Allergology international : official journal of the Japanese Society of Allergology.
[13] D. D. Briggs,et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. , 2000, Chest.
[14] R. Pauwels,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.
[15] L. Pini,et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest , 2002, Thorax.
[16] R. Berger,et al. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. , 1988, Chest.
[17] J. Stocks,et al. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. , 1995, The European respiratory journal.
[18] J. Ramsdell,et al. Determination of bronchodilation in the clinical pulmonary function laboratory. Role of changes in static lung volumes. , 1979, Chest.
[19] M. Rué,et al. The bronchodilator test in chronic obstructive pulmonary disease: interpretation methods. , 2007, Respiratory medicine.
[20] A. Gulsvik,et al. Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. , 2007, Respiratory medicine.
[21] F Kummer,et al. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. , 2002, The European respiratory journal.
[22] L. Forkert,et al. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. , 2002, Chest.
[23] N. Meslier,et al. Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. , 1989, The European respiratory journal.
[24] The one best test for evaluating the effects of bronchodilator therapy. , 1977, Chest.
[25] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[26] G. Viegi,et al. Standardisation of the measurement of lung volumes , 2005, European Respiratory Journal.
[27] A. Rossi,et al. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease. , 2005, Pulmonary pharmacology & therapeutics.
[28] A Pedotti,et al. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD , 2005, Thorax.
[29] R. Light,et al. Should the FVC be considered in evaluating response to bronchodilator? , 1983, Chest.
[30] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[31] A. Foresi,et al. Effect of heliox breathing on dynamic hyperinflation in COPD patients. , 2004, Chest.
[32] N. Anthonisen,et al. Bronchodilator response in chronic obstructive pulmonary disease. , 1986, The American review of respiratory disease.
[33] P. Chanez,et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. , 2007, Pulmonary pharmacology & therapeutics.
[34] F. García-Río,et al. Spirometric reference equations for European females and males aged 65–85 yrs , 2004, European Respiratory Journal.
[35] M. Cazzola,et al. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. , 1998, Respiratory medicine.
[36] T. Schermer,et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. , 2007, Respiratory medicine.
[37] Anthonisen Nr,et al. Bronchodilator response in chronic obstructive pulmonary disease. , 1986 .
[38] K. P. Van de Woestijne,et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. , 2000, Journal of applied physiology.
[39] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[40] Standardized lung function testing. Official statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[41] R. Pellegrino,et al. Assessing the reversibility of airway obstruction. , 1998, Chest.
[42] P. Chanez,et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial , 2007 .
[43] A. Dirksen,et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[44] T. Similowski,et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. , 1998, The European respiratory journal.
[45] M Cazzola,et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD , 2003, European Respiratory Journal.
[46] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[47] J. Hankinson,et al. SERIES ''ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING'' Edited by V. Brusasco, R. Crapo and G. Viegi Number 5 in this Series Interpretative strategies for lung function tests , 2005 .
[48] D. O’Donnell,et al. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[49] D. O’Donnell. Is sustained pharmacologic lung volume reduction now possible in COPD? , 2006, Chest.